CA2859934A1 - Comete de hayley ii - Google Patents
Comete de hayley ii Download PDFInfo
- Publication number
- CA2859934A1 CA2859934A1 CA2859934A CA2859934A CA2859934A1 CA 2859934 A1 CA2859934 A1 CA 2859934A1 CA 2859934 A CA2859934 A CA 2859934A CA 2859934 A CA2859934 A CA 2859934A CA 2859934 A1 CA2859934 A1 CA 2859934A1
- Authority
- CA
- Canada
- Prior art keywords
- cultivar
- cannabidiolic acid
- cannabis
- cannabinoid
- profile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H1/00—Processes for modifying genotypes ; Plants characterised by associated natural traits
- A01H1/04—Processes of selection involving genotypic or phenotypic markers; Methods of using phenotypic markers for selection
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Developmental Biology & Embryology (AREA)
- Environmental Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2859934A CA2859934A1 (fr) | 2014-09-22 | 2014-09-22 | Comete de hayley ii |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2859934A CA2859934A1 (fr) | 2014-09-22 | 2014-09-22 | Comete de hayley ii |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2859934A1 true CA2859934A1 (fr) | 2016-03-22 |
Family
ID=55539873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2859934A Abandoned CA2859934A1 (fr) | 2014-09-22 | 2014-09-22 | Comete de hayley ii |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2859934A1 (fr) |
Cited By (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2541191A (en) * | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| US10092525B2 (en) | 2014-10-14 | 2018-10-09 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
| CN108743571A (zh) * | 2018-08-07 | 2018-11-06 | 云南汉木森生物科技有限责任公司 | 预防、治疗癫痫的药物组合物及其制备方法 |
| CN110632224A (zh) * | 2019-09-16 | 2019-12-31 | 福建省中科生物股份有限公司 | 一种麻类植物指纹图谱的建立方法 |
| US10583096B2 (en) | 2016-03-31 | 2020-03-10 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10603288B2 (en) | 2014-06-17 | 2020-03-31 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10709671B2 (en) | 2015-06-17 | 2020-07-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10729665B2 (en) | 2011-09-29 | 2020-08-04 | Gw Pharma Limited | Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| US10765643B2 (en) | 2014-10-14 | 2020-09-08 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
| US10918608B2 (en) | 2014-10-14 | 2021-02-16 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
| US11065227B2 (en) | 2016-08-25 | 2021-07-20 | GW Research Limited | Use of cannabinoids in the treatment of multiple myeloma |
| US11160795B2 (en) | 2020-02-27 | 2021-11-02 | GW Research Limited | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
| US11229612B2 (en) | 2016-07-01 | 2022-01-25 | GW Research Limited | Parenteral formulations |
| US11291631B2 (en) | 2016-07-01 | 2022-04-05 | GW Research Limited | Oral cannabinoid formulations |
| US11426362B2 (en) | 2017-02-17 | 2022-08-30 | GW Research Limited | Oral cannabinoid formulations |
| US11679087B2 (en) | 2016-12-16 | 2023-06-20 | GW Research Limited | Use of cannabinoids in the treatment of Angelman syndrome |
| US11806319B2 (en) | 2018-01-03 | 2023-11-07 | GW Research Limited | Pharmaceutical composition comprising a cannabinoid |
| US12161607B2 (en) | 2017-02-27 | 2024-12-10 | Jazz Pharmaceuticals Research Uk Limited | Combination of cannabinoids in the treatment of leukemia |
| US12263139B2 (en) | 2017-06-23 | 2025-04-01 | Jazz Pharmaceuticals Research Uk Limited | Use of cannabidiol in the treatment of tuberous sclerosis complex |
| US12357586B2 (en) | 2011-01-04 | 2025-07-15 | Jazz Pharmaceuticals Research Uk Limited | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| US12383567B2 (en) | 2017-12-01 | 2025-08-12 | Jazz Pharmaceuticals Research Uk Limited | Use of cannabinoids in the treatment of epilepsy |
| US12569505B2 (en) | 2022-08-12 | 2026-03-10 | Jazz Pharmaceuticals Research Uk Limited | Oral solid dosage forms comprising cannabinoids |
| US12616705B2 (en) | 2016-12-16 | 2026-05-05 | Jazz Pharmaceuticals Research Uk Limited | Use of cannabinoids in the treatment of Angelman syndrome |
-
2014
- 2014-09-22 CA CA2859934A patent/CA2859934A1/fr not_active Abandoned
Cited By (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12357586B2 (en) | 2011-01-04 | 2025-07-15 | Jazz Pharmaceuticals Research Uk Limited | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| US11318109B2 (en) | 2011-09-29 | 2022-05-03 | Gw Pharma Limited | Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| US12121499B2 (en) | 2011-09-29 | 2024-10-22 | Gw Pharma Ltd. | Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| US10729665B2 (en) | 2011-09-29 | 2020-08-04 | Gw Pharma Limited | Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| US11766411B2 (en) | 2014-06-17 | 2023-09-26 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11963937B2 (en) | 2014-06-17 | 2024-04-23 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11311498B2 (en) | 2014-06-17 | 2022-04-26 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10603288B2 (en) | 2014-06-17 | 2020-03-31 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11701330B2 (en) | 2014-06-17 | 2023-07-18 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11154516B2 (en) | 2014-06-17 | 2021-10-26 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10966939B2 (en) | 2014-10-14 | 2021-04-06 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11154517B2 (en) | 2014-10-14 | 2021-10-26 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10765643B2 (en) | 2014-10-14 | 2020-09-08 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
| US10111840B2 (en) | 2014-10-14 | 2018-10-30 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
| US10849860B2 (en) | 2014-10-14 | 2020-12-01 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US12318356B2 (en) | 2014-10-14 | 2025-06-03 | Jazz Pharmaceuticals Research Uk Limited | Use of cannabinoids in the treatment of epilepsy |
| US10918608B2 (en) | 2014-10-14 | 2021-02-16 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
| US10137095B2 (en) | 2014-10-14 | 2018-11-27 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
| US11065209B2 (en) | 2014-10-14 | 2021-07-20 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
| US10709674B2 (en) | 2014-10-14 | 2020-07-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11096905B2 (en) | 2014-10-14 | 2021-08-24 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10092525B2 (en) | 2014-10-14 | 2018-10-09 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
| US11400055B2 (en) | 2014-10-14 | 2022-08-02 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
| US12427160B2 (en) | 2014-10-14 | 2025-09-30 | Jazz Pharmaceuticals Research Uk Limited | Use of cannabinoids in the treatment of epilepsy |
| US10709673B2 (en) | 2014-10-14 | 2020-07-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11633369B2 (en) | 2014-10-14 | 2023-04-25 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11446258B2 (en) | 2014-10-14 | 2022-09-20 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10709671B2 (en) | 2015-06-17 | 2020-07-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11357741B2 (en) | 2015-06-17 | 2022-06-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US12064399B2 (en) | 2015-06-17 | 2024-08-20 | Jazz Pharmaceuticals Research Uk Limited | Use of cannabinoids in the treatment of epilepsy |
| EP3769755A1 (fr) | 2015-08-10 | 2021-01-27 | GW Research Limited | Utilisation de l acide cannabidiolique dans le traitement de l'épilepsie |
| US11147783B2 (en) | 2015-08-10 | 2021-10-19 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| GB2541191A (en) * | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| US11684598B2 (en) | 2015-08-10 | 2023-06-27 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10583096B2 (en) | 2016-03-31 | 2020-03-10 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US12213985B2 (en) | 2016-07-01 | 2025-02-04 | Jazz Pharmaceuticals Research Uk Limited | Oral cannabinoid formulations |
| US12064398B2 (en) | 2016-07-01 | 2024-08-20 | Jazz Pharmaceuticals Research Uk Limited | Parenteral formulations |
| US11229612B2 (en) | 2016-07-01 | 2022-01-25 | GW Research Limited | Parenteral formulations |
| US11291631B2 (en) | 2016-07-01 | 2022-04-05 | GW Research Limited | Oral cannabinoid formulations |
| US11065227B2 (en) | 2016-08-25 | 2021-07-20 | GW Research Limited | Use of cannabinoids in the treatment of multiple myeloma |
| US11679087B2 (en) | 2016-12-16 | 2023-06-20 | GW Research Limited | Use of cannabinoids in the treatment of Angelman syndrome |
| US12616705B2 (en) | 2016-12-16 | 2026-05-05 | Jazz Pharmaceuticals Research Uk Limited | Use of cannabinoids in the treatment of Angelman syndrome |
| US11426362B2 (en) | 2017-02-17 | 2022-08-30 | GW Research Limited | Oral cannabinoid formulations |
| US12161607B2 (en) | 2017-02-27 | 2024-12-10 | Jazz Pharmaceuticals Research Uk Limited | Combination of cannabinoids in the treatment of leukemia |
| US12263139B2 (en) | 2017-06-23 | 2025-04-01 | Jazz Pharmaceuticals Research Uk Limited | Use of cannabidiol in the treatment of tuberous sclerosis complex |
| US12383567B2 (en) | 2017-12-01 | 2025-08-12 | Jazz Pharmaceuticals Research Uk Limited | Use of cannabinoids in the treatment of epilepsy |
| US11806319B2 (en) | 2018-01-03 | 2023-11-07 | GW Research Limited | Pharmaceutical composition comprising a cannabinoid |
| CN108743571B (zh) * | 2018-08-07 | 2020-10-02 | 云南汉木森生物科技有限责任公司 | 预防、治疗癫痫的药物组合物及其制备方法 |
| CN108743571A (zh) * | 2018-08-07 | 2018-11-06 | 云南汉木森生物科技有限责任公司 | 预防、治疗癫痫的药物组合物及其制备方法 |
| CN110632224B (zh) * | 2019-09-16 | 2022-02-15 | 福建省中科生物股份有限公司 | 一种麻类植物指纹图谱的建立方法 |
| CN110632224A (zh) * | 2019-09-16 | 2019-12-31 | 福建省中科生物股份有限公司 | 一种麻类植物指纹图谱的建立方法 |
| US12102619B2 (en) | 2020-02-27 | 2024-10-01 | Jazz Pharmaceuticals Research Uk Limited | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| US11406623B2 (en) | 2020-02-27 | 2022-08-09 | GW Research Limited | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| US11160795B2 (en) | 2020-02-27 | 2021-11-02 | GW Research Limited | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
| US12569505B2 (en) | 2022-08-12 | 2026-03-10 | Jazz Pharmaceuticals Research Uk Limited | Oral solid dosage forms comprising cannabinoids |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2859934A1 (fr) | Comete de hayley ii | |
| CA2737447A1 (fr) | "hayley's comet" | |
| Jiang | Natural forms of vitamin E: metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy | |
| Kaplan et al. | Adipocyte progenitor cells initiate monocyte chemoattractant protein-1-mediated macrophage accumulation in visceral adipose tissue | |
| Zhou et al. | Oxidative stress in the pathogenesis of psoriasis | |
| Huang | Regulation of phenotypic transitions in the fungal pathogen Candida albicans | |
| Liu et al. | Effects of manganese deficiency on the microstructure of proximal tibia and OPG/RANKL gene expression in chicks | |
| Kipper et al. | Meta-analysis of the effects of endoparasites on pig performance | |
| Long et al. | Effect and mechanism of citral against methicillin‐resistant Staphylococcus aureus in vivo | |
| JP2019535681A5 (fr) | ||
| Rock et al. | Synergy between cannabidiol, cannabidiolic acid, and Δ⁹-tetrahydrocannabinol in the regulation of emesis in the Suncus murinus (house musk shrew). | |
| Gao et al. | Supplementation of xanthophylls decreased proinflammatory and increased anti-inflammatory cytokines in hens and chicks | |
| Wang et al. | Application of exogenous auxin and gibberellin regulates the bolting of lettuce (Lactuca sativa L.) | |
| Lauridsen et al. | Composition of α-tocopherol and fatty acids in porcine tissues after dietary supplementation with vitamin E and different fat sources | |
| Nguyen et al. | Growth performance and carcass characteristics of Australian prime lambs supplemented with pellets containing canola oil or flaxseed oil | |
| WO2011104900A1 (fr) | Agent antifongique | |
| Basuki | Analisis tingkat preferensi petani terhadap karakterisitik hasil dan kualitas bawang merah varietas lokal dan impor | |
| CA2859927A1 (fr) | Empreinte genetique gcg et profil clhp | |
| RU2020119597A (ru) | Композиция для лечения пациента с респираторным заболеванием, обусловленным хроническим воспалением, способ получения и применение указанной композиции | |
| Dąbrowski et al. | Cannabinoids from Cannabis sp.: Mechanism of their activity and potential health benefits in human body | |
| WO2017220044A3 (fr) | Composition pharmaceutique de bifonazole et son effet de protection du foie | |
| TWI702959B (zh) | 開發黃花蟛蜞菊的標準化與功效最佳化的草藥抽出物以及其用於治療疾病的用途 | |
| BR112022011326A2 (pt) | Conjugado entre um biopolímero e um agente antimicrobiano fotoativável para combate de doenças fúngicas de interesse agrícola e métodos para produção dos ditos conjugados | |
| Henning et al. | Registration of High Alpha‐Acid Male Hop Germplasm USDA 21267M | |
| US20240341254A1 (en) | Varin profiles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20170922 |